Chemistry:Fruquintinib
 | |
| Clinical data | |
|---|---|
| Trade names | Fruzaqla |
| Other names | HMPL-013 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H19N3O5 |
| Molar mass | 393.399 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fruquintinib, sold under the brand name Fruzaqla, is an anti-cancer medication used for the treatment of colorectal cancer.[1] Fruquintinib is a kinase inhibitor.[1]
The most common adverse reactions include hypertension, palmar-plantar erythrodysesthesia, proteinuria, dysphonia, abdominal pain, diarrhea, and asthenia.[2]
Fruquintinib was approved for medical use in the United States in November 2023.[2][3]
Medical uses
Fruquintinib is indicated for adults with metastatic colorectal cancer who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.[1][2][4][5]
History
Efficacy was evaluated in FRESCO-2 (NCT04322539) and FRESCO (NCT02314819).[2] FRESCO-2 (NCT04322539), an international, multicenter, randomized, double-blind, placebo-controlled trial, evaluated 691 participants with metastatic colorectal cancer who had disease progression during or after prior fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, an anti-VEGF biological therapy an anti-EGFR biological therapy if RAS wild type, and at least one of trifluridine/tipiracil or regorafenib.[2] FRESCO, a multicenter, placebo-controlled trial conducted in China, evaluated 416 participants with metastatic colorectal cancer who had disease progression during or after prior fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy.[2]
References
- ↑ 1.0 1.1 1.2 1.3 "Fruzaqla- fruquintinib capsule". 14 November 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=186d786e-dc8a-45f2-b5e1-01ac0201879f.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "FDA approves fruquintinib in refractory metastatic colorectal cancer". 8 November 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer.
This article incorporates text from this source, which is in the public domain.
- ↑ "Takeda Receives U.S. FDA Approval of Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer" (Press release). Takeda. 8 November 2023. Archived from the original on 8 November 2023. Retrieved 10 November 2023 – via Business Wire.
- ↑ "Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review". Translational Cancer Research 11 (1): 276–287. January 2022. doi:10.21037/tcr-20-3539. PMID 35261903.
- ↑ "Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer". International Journal of Molecular Sciences 24 (6): 5840. March 2023. doi:10.3390/ijms24065840. PMID 36982913.
External links
- Clinical trial number NCT04322539 for "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer (FRESCO-2)" at ClinicalTrials.gov
- Clinical trial number NCT02314819 for "A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer participants （FRESCO) (FRESCO)" at ClinicalTrials.gov
 |  |
